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ABSTRACT 15 
Background: Environmental exposure to phthalates may contribute to an increased risk of 16 
asthma in children and adults. We aimed to assess the direction and strength of the 17 
association between urinary phthalates metabolites and current asthma in children and 18 
adults that participated in the National Health and Nutrition Examination Survey (NHANES) 19 
2007-2012. 20 
Methods: Data on ten urinary phthalate metabolites, self-reported questionnaires, 21 
spirometry measures, and covariates were obtained from 7765 participants (28.1% were 22 
children aged 6-17 years) taking part in the NHANES 2007-2012. Asthma was assessed 23 
using self-reported questionnaires for children and adults; and via spirometry measures for 24 
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adults alone. We used crude and adjusted logistic regression models to estimate the odds 25 
ratios (ORs) and 95% confidence interval (CI) per one log10 unit change in the concentration 26 
of phthalate metabolites. We further modeled the effect modification by sex. 27 
Results: Out of 10 metabolites, only mono-benzyl phthalate (MBzP) was positively 28 
associated with the prevalence of self-reported asthma in children, after adjusting for a range 29 
of potential confounders (Odds Ratio: 1.54; 95% Confidence Interval: 1.05-2.27).  No 30 
significant relationship was observed for adults. The association of mono-ethyl phthalate 31 
(MEP) was modified by sex, with significantly increased odds of asthma among males [boys 32 
(2.00; 1.14-3.51); adult males (1.32; 1.04-1.69)]. While no other phthalates showed a 33 
positive relationship with current asthma in males, mono (carboxynonyl) phthalate (MCNP) 34 
and mono (3-carboxylpropyl) phthalate (MCPP) were inversely associated with 35 
spirometrically-defined asthma in adult females. A sex-specific relationship in adults was 36 
evident when spirometry, but not self-reported measures were used to define asthma. 37 
Conclusion: We found no clear association between exposure to phthalates and current 38 
asthma, except for a significant relationship between MBzP metabolites and self-reported 39 
asthma in children. As a result, exposure to phthalates and asthma development and/or 40 
exacerbations remains controversial, suggesting a need for a well-designed longitudinal 41 
study. 42 
Keywords: phthalate metabolites, mono-benzyl phthalate, childhood asthma, adult asthma, 43 
NHANES 44 
Introduction 45 
For the past two decades, the prevalence of asthma has substantially increased in 46 
both the developed and developing countries (Osborne et al. 2017). The International Study 47 
of Asthma and Allergies in Childhood (ISAAC) study demonstrated that across 37 countries 48 
including the US and the UK, the average prevalence of asthma in 2006 amongst children 49 
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aged 6-7 years was 12.6% (Asher et al. 2006). The Global Burden of Disease attributed to 50 
asthma is predicted to be about 11 million years of life lost (YLLs) and 25 million disability-51 
adjusted life years (DALYs) per year (Osborne et al. 2017). 52 
Asthma is a common chronic disease in children and adults characterised by airway 53 
inflammation and increased mucus production - leading to airway obstruction (Khalili et al. 54 
2018).  It is estimated by the US Centers for Disease Control and Prevention (CDC) that 55 
6.8% of US working adults have current asthma – defined as having had at least one asthma 56 
attack or visit the emergency department (ED) for asthma in the past 12 months (Mazurek et 57 
al. 2018). The disease is a potential threat to children’s growth and development including 58 
their educational achievement (Nurmagambetov et al. 2018). In 2017, the prevalence of 59 
asthma was reported in approximately 6.2 million children in the US – about 8.4% of children 60 
under the age of 18 (CDC 2017). The US annual economic costs associated with asthma 61 
have been estimated at $81 billion for 2013, including treatment costs and mortality costs 62 
valued using the value of statistical life and lost work and school days (Nurmagambetov et 63 
al. 2018). The root causes of asthma have not been fully elucidated, but genetic 64 
predisposition, and environmental factors including allergens and chemicals (such as 65 
phthalates) as well as gene-environment interactions, have been suggested as important 66 
risk factors for asthma pathogenesis and exacerbations (Wang et al. 2015; Sordillo et al. 67 
2015; Surdu et al. 2005) 68 
Phthalates are synthetic chemicals produced by reacting phthalic anhydride with 69 
different chain lengths of alcohol(s) which may vary from single chain alcohol (such as 70 
methanol) to multiple chain alcohol (such as tridecyl alcohol) (Benjamin et al. 2017). They 71 
are mainly classified into two types – high (HMW) and low molecular weight (LMW) 72 
phthalates - and their uses may in part depend on their molecular weight (Table 1) (Braun et 73 
al. 2013; Benjamin et al. 2017). Phthalates are omnipresent and are not covalently bound to 74 
the consumer products; they easily leach out and make their way to the environment (Tsai et 75 
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al. 2012). Humans are exposed to these chemicals through several routes of exposure 76 
including water, breathing air, dermal contact, during medical treatment and, importantly, via 77 
food (Benjamin et al. 2017).  78 
Although phthalates are easily bio-transformed and excreted (leading to lesser 79 
bioaccumulation), regular exposure in humans may exacerbate the risk of developing 80 
asthma or prolong its prevalence by binding with and activating peroxisome proliferator-81 
activated receptors (PPARs) which mediate anti-inflammatory effects in the lungs and 82 
immune systems (Bolling et al. 2013); increasing the proliferation of the bronchial muscle 83 
cells which may lead to airways remodelling (Kue et al. 2011); promoting the production of 84 
pro-inflammatory cytokines IL-6 and IL-8 in the airway epithelial cells (Jepsen et al. 2004); 85 
and/or; acting as an adjuvants by enhancing macrophage production of inflammatory 86 
cytokines and chemokines (Nishioka et al. 2012) 87 
Several epidemiological studies have demonstrated that regular exposure to 88 
phthalates is associated with an increased risk of non-communicable chronic diseases 89 
including cardiovascular diseases and diabetes (Dong et al. 2017; Bai et al. 2017). Limited 90 
information is known about the association between phthalates exposure and the prevalence 91 
of asthma (Benjamin et al. 2017), with available evidence producing inconsistent results. A 92 
meta-analysis demonstrated that post-natal exposure to di-(2-ethylhexyl) phthalate (DEHP) 93 
and butylbenzyl phthalate (BBzP) from dust and prenatal urinary mono-benzyl phthalate 94 
(MBzP) were significantly associated with childhood asthma (Li et al. 2017).  95 
In contrast, a recent study has shown that both LMW and HMW phthalates (including 96 
DEHP) were not associated with the report of doctor-diagnosed asthma (Vernet et al. 2017). 97 
Previous research found that the urinary concentration of MBzP metabolite was associated 98 
with self-reported asthma in adults but not in children (Hoppin et al. 2013). These 99 
inconsistencies need to be addressed with more research into the potential association 100 
between phthalates and asthma in children and adults using a large cross-sectional 101 
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secondary data and better outcome measures (for example spirometry and questionnaire 102 
data). 103 
In addition, the development and/or exacerbation of asthma may be sex-specific. 104 
Whilst the prevalence of asthma, in general, is greater in females than in males (CDC 2008), 105 
investigation at a specific time point revealed otherwise. Before age 13-14 years, the 106 
incidence and prevalence of asthma with increased wheeze, use of asthma medications and 107 
serum IgE level are greater among boys than among girls (Wijga et al. 2011; Almqvist et al. 108 
2008; Bjornson and Mitchell 2000). By contrast, studies through puberty and beyond have 109 
found a greater increase in the incidence and prevalence of asthma among adolescent and 110 
young adult females (CDC 2008; De Marco et al. 2000). Importantly, a prospective cohort 111 
study demonstrated that the relationship between phthalates and asthma may be modified 112 
by sex (Buckley et al. 2018), with 5-year old boys at increased odds of asthma occurrence 113 
following exposures to mono (2-ethylhexyl) phthalate (MEHP) and mono-ethyl phthalate 114 
(MEP) (Ku et al. 2015). 115 
In the current study, we polled the National Health and Nutrition Examination Survey 116 
(NHANES) 2007-2012 data to examine the direction and strength of the association between 117 
urinary phthalate metabolites and current asthma in children and adults. As a secondary 118 
aim, we stratified the data based on the participant sex, to investigate whether the effect 119 
measure was modified by sex in both children and adults. 120 
INSERT TABLE 1 NEAR HERE 121 
Methods 122 
Study population 123 
NHANES is a nationally representative, multi-stage, population-based, cross-124 
sectional study carried out by the United State National Centre for Health Statistics (NCHS). 125 
It was designed to assess the health and nutritional status of civilian, non-institutionalized 126 
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children and adults in the United States. Respondents for our study were children aged 127 
between 6 and 17 years, and adults aged 18 and 79 years, who were randomly selected by 128 
the NHANES for urinary phthalates measurement; and who had complete information on 129 
self-reported questionnaires, spirometry, and confounding variables. Participants aged 80 130 
years and over were excluded in order to reduce biases resulting from the non-131 
representation of the older adults who are institutionalised after 80 years.  132 
Data were pooled from three independent cross-sectional waves (2007-2008, 2009-133 
2010 and 2011-2012), providing an initial total sample of 30,442 participants (11,823 134 
children and 18,619 adults). Urinary phthalates concentrations were determined for 7765 135 
subsets (2180 children and 5585 adults), therefore only these participants were used for 136 
analysis. All selected participants provided informed consent in writing during the period of 137 
recruitment (NHANES 2017) 138 
Measurement of phthalate metabolites 139 
Phthalate metabolites were measured in a spot urine sample of a randomly selected 140 
one-third sub-sample of the study respondents. These collected samples were frozen at the 141 
temperature of -20˚C and shipped to the division of Environmental Health Laboratory 142 
Sciences, National Centre for Environmental Health, CDC for the analysis of various 143 
phthalate metabolites. In order to reduce the possibility of exposure misclassification 144 
(James-Todd et al. 2016), phthalate metabolites were measured instead of their parent 145 
compound. A full description of the analytical methods employed for the measurement of 146 
phthalates metabolites have been described elsewhere (Laboratory Procedure Manual 147 
2013). 148 
A combination of phthalate metabolites that have been previously studied and those 149 
that were measured in all the three cross-sectional waves, with more than 60% of the 150 
sample concentrations at or above the limit of detection (LOD) (James-Todd et al 2016) 151 
7 
 
 
were selected for this project. These included ten (10) phthalate metabolites: mono 152 
(carboxynonyl) phthalate (MCNP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), 153 
MEHP, mono-(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) 154 
phthalate (MEOHP), mono-n-butyl phthalate (MnBP), mono-iso-butyl phthalate (MiBP), 155 
MBzP, MEP, and mono (3-carboxylpropyl) phthalate (MCPP).  156 
Given that the LOD for phthalate metabolites differed across each survey cycle, the 157 
maximum limit of detection (LODmax) was used to standardize each phthalate detection limits 158 
in the three cross-sectional waves (Varshavsky et al. 2018). Thus, all concentrations below 159 
the LODmax were substituted with the value of LODmax divided by the square root of two 160 
(Varshavsky et al. 2018). 161 
 Asthma data 162 
Self-reported questionnaire data 163 
NHANES collected information on asthma and associated symptoms using a self-164 
administered questionnaire completed at the NHANES clinic visit. Following the 165 
recommendation from the European birth cohort study (Carlsen et al. 2012), current asthma 166 
was defined by respondents giving a positive response to both questions: “Has a doctor or 167 
other health professional ever told you that you have asthma?” and “In the past 12 months 168 
(have you/has SP) had wheezing or whistling in (your/his/her) chest?”  169 
Spirometry data 170 
Spirometry data were available in all cross-sectional waves and were also used for 171 
asthma determination. Participants aged 6 to 79 years were considered eligible for 172 
spirometry testing. Respondents were excluded if they: had current chest pain or physical 173 
problems with forceful expiration; had recent chest, eye or abdominal surgery; had a heart 174 
problem (such as heart attack), stroke or tuberculosis; were taking supplementary oxygen; 175 
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had a collapsed lung or detached retina; had painful ear problems or had coughed up blood 176 
recently (NHANES 2014).  177 
Spirometry testing for eligible participants was performed following the procedures 178 
recommended by the American Thoracic Society (ATS). The protocol and procedures for 179 
spirometry testing have been described elsewhere (NHANES 2008). The baseline 180 
spirometry results of forced expiratory volume in one second (FEV1), forced vital capacity 181 
(FVC) and FEV1/FVC% were determined by adopting a normal equation for spirometry 182 
parameters of the US population which takes into account each respondent’s age, sex, 183 
weight, height, and race/ethnicity (NHANES 2014).  184 
Based on the guidelines set from the International Consensus Statement between 185 
the ATS and the European Respiratory Society (ERS) which suggest the presence of airflow 186 
obstruction when the FEV1/FVC ratio was less than 70% (Cerveri et al. 2008), current 187 
untreated asthma was defined via spirometry results as respondents with an FEV1/FVC of 188 
<70% (Abo-Zaid et al. 2018). Analyses using self-reported but not with spirometry data were 189 
performed for children. This is because accuracy and precision suffer in spirometry testing 190 
involving children (Murray et al. 2016) 191 
Confounding variables 192 
Information on covariates was obtained from the NHANES. These covariates were 193 
determined using the self-reported questionnaire, physical examination, and laboratory 194 
measurements. Age, sex, race/ethnicity, and poverty status (which serves as a proxy for 195 
socioeconomic status (SES)) were ascertained via questionnaire. Poverty status was 196 
defined by the poverty income ratio (PIR) which was calculated by dividing the family income 197 
by the poverty guidelines of a specific survey year. Race/ethnicity was classified as “non-198 
Hispanic white” (referent group), “non-Hispanic black”, “Mexican-American,” and “Other.”  199 
9 
 
 
Waist circumference in centimetres (cm) was used as a measure of overweight since 200 
it gives a better measure of obesity-related health risks than body mass index (BMI) 201 
(Janssen et al. 2004). Urinary creatinine concentrations were measured using Roche/Hitachi 202 
Modular P chemistry analyser and Synchron CX3 clinical analyser (Beckman, California, 203 
USA). Serum cotinine level (a biomarker for smoking status) was categorized as <LOD 204 
(<0.015) nanogram/millilitre (ng/ml) (referent); low levels (≥0.015 – 10 ng/ml); and high levels 205 
(≥10 ng/ml). 206 
Statistical analysis 207 
The Spearman’s rank correlation coefficient was used to examine phthalate metabolites 208 
correlation. Phthalate metabolite was considered to have a strong correlation with a 209 
Spearman’s correlation coefficient (rs) greater than or equal to 0.7 (rs ≥ 0.7).  MEHP (a 210 
primary metabolite) and MECPP, MEHHP and MEOHP (secondary metabolites) of DEHP 211 
were strongly correlated with one another (with a value of rs between 0.73-0.98) (Additional 212 
file 1: Table S1). Therefore, these metabolites were not separately analysed given their 213 
strong correlation and common source; the molar sum of DEHP denoted as “ΣDEHP,” was 214 
used instead (Hoppin et al. 2013).  215 
Sampling weights, stratification, and clustering provided in the NHANES study were 216 
applied to all statistical analysis in order to account for the complex, multistage sampling 217 
design employed in the selection of the representative non-institutionalized US population as 218 
well as obtaining accurate estimates that will not overstate the statistical significance. 219 
Following the NHANES analytical guidelines (Johnson et al. 2013), a new sampling weight 220 
for the combined survey cycle was constructed by dividing the 2-year weights for each cycle 221 
by 3 which was applied to the data via the Stata command [svyset] prior to analysis.  222 
Descriptive statistics (weighted means, standard deviation, weighted percentages 223 
and 95% confidence interval (CI)) were used to describe the demographics of all children 224 
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and adults and their respective subsets with measured urinary phthalate metabolite 225 
concentrations. The distribution of urinary phthalate metabolites were presented for both 226 
children and adults using weighted geometric means, 95% CI, and percentiles.  227 
Logistic regression models (model 1 and 2) were used to determine the cross-228 
sectional measure of the association between urinary phthalate metabolites (continuous) 229 
and current asthma (dichotomous outcome) by estimating the odds ratio (ORs) and 95% CIs 230 
per one log10 unit change in the concentration of phthalate metabolites. Model 1 was 231 
presented as unadjusted ORs and 95% CI. Model 2 was adjusted for urinary creatinine (log10 232 
transformed, continuous) in addition to other potential confounding variables.  233 
Potential confounders included in this analysis were those suggested as being linked 234 
with phthalate metabolites and/or asthma (Hoppin et al. 2013; James-Todd et al. 2016; 235 
Gascon et al. 2015; Buckley et al. 2018). These variables included age, sex, race/ethnicity, 236 
waist circumference, PIR, cotinine, and urinary creatinine. The analysis was further stratified 237 
by sex for both children and adults by applying similar statistical modeling.  238 
In order to assess the robustness of our findings, a sensitivity analysis was 239 
performed. Exposure-response relationships were examined by modeling the associations 240 
between tertiles of phthalate creatinine-corrected concentrations and asthma, with the lowest 241 
tertile considered as the reference category (Buckley et al. 2018). Tertiles were categorised 242 
separately for children and adults such that each tertile contained an equal number of 243 
participants. While results for each phthalate metabolite were presented as crude and 244 
adjusted ORs and 95% CIs, only adjusted models were shown for effect modifications by 245 
sex and sensitivity analyses. All statistical analyses were conducted using STATA version 246 
15.0 (College Station, Texas, USA). 247 
 248 
 249 
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Results 250 
The demographic characteristics of all children (n=11,823) and the subset with 251 
measured urinary phthalate concentrations (n=2180), who participated in the NHANES 252 
2007-2012 are shown in Table 2. Approximately 8% of children in both groups had self-253 
reported asthma. With spirometry measures, the proportion of respondents with current 254 
asthma dropped to less than 2%. The weighted proportions of all children belonging to any 255 
race or living below the poverty threshold [poverty-to-income ratio (PIR)] were somewhat 256 
similar to those with measured phthalate metabolites. 257 
INSERT TABLE 2 NEAR HERE 258 
Of the 30,442 respondents in the NHANES 2007-2012 cross-sections, a total of 259 
61.2% (n=18,619) were adults - with approximately a third (n=5585) of the participants sub-260 
sampled for phthalate metabolite levels (Table 3). Although adults with detectable phthalate 261 
metabolite values were slightly younger when compared with all adults, there was no 262 
difference in the weighted proportions of the subjects belonging to any race or living below 263 
the poverty threshold [poverty-to-income ratio (PIR) <1).  264 
INSERT TABLE 3 NEAR HERE 265 
Self-reported asthma was seen in nearly 6% of both groups. With the spirometry 266 
measure, the proportion of asthmatics was more than doubled. This is expected given the 267 
nature of the US healthcare system with many adults in the US without health insurance and 268 
thus with undiagnosed asthma (Baldacci et al. 2015). 269 
All participants (children and adults) had detectable concentrations of both LMW and 270 
HMW phthalate metabolites (detection frequency >60%) (Table 4 and 5). With regard to 271 
LMW phthalates, MEP had the highest mean concentrations for both children and adults. For 272 
HMW phthalates, MECPP showed the highest in both groups.  273 
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The crude and adjusted model of associations between the different phthalate 274 
metabolites and self-reported asthma in children are shown in Figure 1a and 1b, 275 
respectively. Self-reported childhood asthma was positively associated with MEP (1.45; 276 
1.10-1.92), MiBP (1.62; 1.12-2.32), MnBP (1.46; 1.05-2.02) and MBzP (1.50; 1.09-2.08) in 277 
the crude analysis; with only MBzP (1.54; 1.05-2.27) reaching statistical significance after 278 
adjusting for confounding variables. 279 
INSERT FIGURE 1A 280 
Figure 1a. Model 1 (crude) - associations of urinary phthalate metabolites with self-reported 281 
asthma in children, NHANES 2007-2012. 282 
Logistic regression modeling was used to access the effect of individual phthalate 283 
metabolites on asthma prevalence, with an odds ratio (OR) presented for 1 log10 unit change 284 
in urinary phthalate concentration. 285 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 286 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-287 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 288 
MECPP, and MEOHP) 289 
FIGURE 1B 290 
Figure 1b. Model 2 (adjusted) - associations of urinary phthalate metabolites with self-291 
reported asthma in children, NHANES 2007-2012.  292 
Logistic regression modeling was used to access the effect of individual phthalate 293 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 294 
urinary phthalate concentration. 295 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 296 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-297 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 298 
MECPP, and MEOHP) 299 
All models were adjusted for age, sex, ethnicity/race, waist circumference, cotinine, poverty, 300 
urinary creatinine 301 
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Stratification by child’s sex revealed that only the association between MEP and 302 
current asthma was modified, with a significant positive relationship among boys (2.00; 1.14-303 
3.51), but not among girls (Figure 2). Effect modification was not observed for MBzP, despite 304 
the significant relationship found in the overall model. 305 
INSERT FIGURE 2 306 
Figure 2. Associations between urinary phthalate metabolites and asthma (self-reported) in 307 
children stratified by sex.  308 
Logistic regression modeling was used to access the effect of individual phthalate 309 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 310 
urinary phthalate concentration. 311 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 312 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-313 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 314 
MECPP, and MEOHP) 315 
All models were adjusted for age, race/ethnicity, waist circumference, poverty, urinary 316 
creatinine, and cotinine. 317 
 318 
 319 
The crude and adjusted analyses of associations between different phthalate 320 
metabolites and self-reported asthma in adults are shown in Figure 3a and 3b, respectively. 321 
No phthalate metabolite showed a clear significant association with self-reported asthma in 322 
either the crude or the adjusted models. Effect modification by adult sex was not observed 323 
between any phthalate metabolites and self-reported asthma (Figure 4).  324 
INSERT FIGURE 3A 325 
Figure 3a. Model 1 (crude) - associations of urinary phthalate metabolites with self-reported 326 
asthma in adults, NHANES 2007-2012.  327 
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 Logistic regression modeling was used to access the effect of individual phthalate 328 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 329 
urinary phthalate concentration. 330 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 331 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-332 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 333 
MECPP, and MEOHP) 334 
INSERT FIGURE 3B 335 
Figure 3b. Model 2 (adjusted) - associations of urinary phthalate metabolites with self-336 
reported asthma in children, NHANES 2007-2012.  337 
Logistic regression modeling was used to access the effect of individual phthalate 338 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 339 
urinary phthalate concentration. 340 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 341 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-342 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 343 
MECPP, and MEOHP) 344 
All models were adjusted for age, sex, ethnicity/race, waist circumference, cotinine, poverty, 345 
urinary creatinine 346 
INSERT FIGURE 4  347 
Figure 4. Associations between urinary phthalate metabolites and asthma (self-reported) in 348 
adults stratified by sex.  349 
Logistic regression modeling was used to access the effect of individual phthalate 350 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 351 
urinary phthalate concentration. 352 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 353 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-354 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 355 
MECPP, and MEOHP) 356 
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All models were adjusted for age, race/ethnicity, waist circumference, urinary creatinine, and 357 
cotinine. 358 
 359 
Association of urinary phthalate metabolites and current asthma in adults were re-360 
analysed using spirometry data, with the results presented in Figure 5a and 5b. MiBP was 361 
inversely associated with asthma in adults in the unadjusted model (0.73; 0.59-0.89), but the 362 
association did not reach statistical significance after adjusting for confounders. No other 363 
phthalate metabolites showed a significant relationship in either the crude nor the adjusted 364 
analyses. 365 
INSERT FIGURE 5A 366 
Figure 5a. Model 1 (crude) - associations of urinary phthalate metabolites with current 367 
asthma (spirometry measure) in adults, NHANES 2007-2012.  368 
 Logistic regression modeling was used to access the effect of individual phthalate 369 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 370 
urinary phthalate concentration. 371 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 372 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-373 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 374 
MECPP, and MEOHP) 375 
INSERT FIGURE 5b 376 
Figure 5b. Model 2 (adjusted) - associations of urinary phthalate metabolites with current 377 
asthma (spirometry measure) in adults, NHANES 2007-2012.  378 
Logistic regression modeling was used to access the effect of individual phthalate 379 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 380 
urinary phthalate concentration. 381 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 382 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-383 
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carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 384 
MECPP, and MEOHP) 385 
All models were adjusted for age, sex, ethnicity/race, waist circumference, cotinine, poverty, 386 
urinary creatinine. 387 
 388 
 389 
The association of current asthma with MEP, MCPP and MCNP were not apparent in 390 
the overall model until after stratification by sex (Figure 6). Similar to the result observed in 391 
children, a positive significant relationship was found between MEP and current asthma 392 
among adult males (1.32; 1.04-1.69) but not for females (1.03; 0.75-1.44). In contrast, MCPP 393 
and MCNP were negatively associated with current asthma in adult females alone. 394 
INSERT FIGURE 6 395 
Figure 6. Associations between urinary phthalate metabolites and current asthma 396 
(spirometry measure in adults stratified by sex.  397 
Logistic regression modeling was used to access the effect of individual phthalate 398 
metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log10 unit change in 399 
urinary phthalate concentration. 400 
MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; 401 
MBzP: mono-benzyl phthalate; MCNP: mono (carboxynonyl) phthalate; MCPP: mono (3-402 
carboxylpropyl) phthalate; ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, 403 
MECPP, and MEOHP) 404 
All models were adjusted for age, race/ethnicity, waist circumference, urinary creatinine and 405 
cotinine. 406 
 407 
Sensitivity analyses examining the exposure-response associations demonstrated 408 
increases or decreases in the odds of current asthma with increasing exposure category 409 
(Additional file 1: Table S2, S3, and S4). Overall, the results were consistent with the primary 410 
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analysis in both children and adults. There was a significant positive association between 411 
MBzP exposure and self-reported asthma in children for the highest tertile relative to the 412 
lowest tertile (1.99; 1.08-3.68), but not with any other phthalate metabolites. For male 413 
children, exposure to the highest tertile of MEP was significantly associated with over a 2-414 
fold increased odds of self-reported asthma compared to the lowest tertile of MEP (2.38; 415 
1.107-5.29). Similarly, adult males in the middle (1.64; 1.01-2.68) and highest tertiles (1.66; 416 
1.07-2.2.59) had an elevated odds of asthma compared to those in the lowest tertiles. With 417 
the exception of MEP, no other phthalate metabolites showed a positive association with 418 
current asthma in males. 419 
Results were, however, less consistent for adult females, with no significant 420 
relationship found using spirometry data as opposed to the inverse association found 421 
between MCNP and MCPP metabolites and current asthma in the primary analysis. 422 
 423 
Discussion 424 
In this study, we observed no clear relationship between phthalate exposure and 425 
asthma, apart from one significant association between MBzP and self-reported asthma in 426 
children. Stratification by sex revealed that both boys and adult males are not at increased 427 
odds of current asthma following exposure to the majority of phthalate metabolites apart 428 
from the MEP metabolite. We found associations of MCNP and MCPP concentrations with 429 
reduced odds of asthma (defined using FEV1/FVC 70% cut off) among adult females. MiBP, 430 
MnBP, and ΣDEHP were not significantly associated with either self-reported or objectively 431 
defined asthma (spirometry measure) in both children and adults.   432 
Whyatt et al. (2014) examined the relationship between the diagnosis of asthma in 433 
children (aged 5-11 years, n= 300) and prenatal exposures BBzP, di-n-butyl phthalate 434 
(DnBP), DEHP and di-ethyl phthalate (DEP) using a longitudinal birth cohort of 727 women 435 
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enrolled between 1998 and 2006. They found that maternal prenatal MBzP and MnBP 436 
concentrations– metabolites of HMW BBzP and DnBP respectively– were significantly 437 
associated with the diagnosis of current asthma and with a history of asthma-like symptoms 438 
(Wyatt et al. 2014). The present study found a significant association between MBzP and 439 
self-reported asthma in children, but no relationship was found for MnBP. 440 
A positive correlation was found between an HMW metabolite, DEHP exposure and 441 
asthma in settled dust (Gascon et al. 2015), but not with MBzP (Bornehag et al. 2004; 442 
Kolarik et al. 2008). A cross-sectional study of 623 Norwegian children aged 10- years old 443 
reported a significant relationship with the highest quartiles of MCNP and mono 444 
(carboxyloctyl) phthalate (MCOP) (Bertelsen et al. 2013). However, we did not find a positive 445 
association of childhood asthma with DEHP or MCNP in either the crude or the adjusted 446 
analyses. This disparity may be attributed in part to the matrix examined, dust (Gascon et al. 447 
2015; Bornehag et al. 2004; Kolarik et al. 2008) versus urine (Bertelsen et al. 2013). Another 448 
possible explanation might be the differences in specimen collection (i.e. the use of first-449 
morning void (Bertelsen et al. 2013) as opposed to spot urine in the present study), as these 450 
may affect the concentrations of phthalate metabolites measured.  451 
MBzP is a primary metabolite of BBzP, an HMW phthalate used in the manufacturing 452 
of toys, PVC materials, child care articles and personal care products, and for 453 
pharmaceutical coatings (Benjamin et al. 2017; Braun et al. 2013). While exposure to some 454 
phthalate compounds, particularly among asthmatics, may be via pharmaceuticals, Hoppin 455 
et al. (2013) suggested that the presence of MBzP in urine is unlikely to be as a result of the 456 
use of asthma medication since BBzP is not approved for pharmaceutical coatings. 457 
Compared with non-asthmatics, Hsu et al. 2011 (Hsu et al. 2012) demonstrated that 458 
asthmatic children had significantly higher levels of BBzP determined in settled dust, even 459 
after controlling for other indoor air pollutants. They proposed that the inhalation of BBzP 460 
19 
 
 
may be an important pathway to the development or exacerbation of asthma in children in 461 
Taiwan (Hsu et al. 2012). 462 
In a study using the NHANES data, Hoppin et al. (2013) showed that HMW phthalate 463 
metabolites, particularly MBzP, were positively associated with current asthma, current 464 
wheeze, current hay fever, and current rhinitis in adults (aged 18 years and older, n=1596). 465 
but not in children (aged 6-17 years, n=779). This disparity with our analysis may be 466 
attributed to the asthma definition and/or the measurement method used. Hoppin et al. 467 
(2013) separated the definition of current asthma and wheeze in their analysis, whereas the 468 
present study combined these self-reported measures. It is also possible that our findings for 469 
children may have occurred by chance alone since no other phthalate analysed showed a 470 
significant relationship in the adjusted models.   471 
We did observe that the weighted geometric mean concentration of MBzP in children 472 
was two-fold the level seen in adults (Table 4 and 5). This suggests that children are more 473 
exposed to MBzP than adults and may be at increased odds of asthma following this 474 
exposure. It is important to note that our findings for children should, however, be interpreted 475 
with caution. While one (MBzP metabolite) out of ten metabolites analysed was positively 476 
associated with asthma, this does not suggest any strong relationship between phthalates 477 
and asthma. For adults, using both self-reported and spirometry data of the present study, 478 
there were no associations between any phthalate metabolite and current asthma. 479 
INSERT TABLE 4 NEAR HERE 480 
INSERT TABLE 5 NEAR HERE 481 
With respect to effect modification by sex, Ku et al. (2015) reported that exposure to 482 
MEP metabolite was significantly associated with an increased odds of asthma among boys, 483 
but not among girls; and this was reflected in our study. Analysis of 240 adult participants 484 
(140 females, 100 males; 20 to 60 years) of NHANES III revealed that MEP levels in urine 485 
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were associated with a reduction in pulmonary function measures (FEV1, FVC) in adult 486 
males alone (Hoppin et al. 2004). A similar study of 3147 participants (aged between 6 and 487 
49 years) found significant associations between MEP, MnBP, MCPP and ΣDEHP exposure, 488 
and a reduction in FEV1 or FVC in men (Cakmak et al. 2014). Although an inverse 489 
association was found between MCPP and MCNP metabolites and current asthma in adult 490 
females, our result for MEP was consistent with previous studies for both boys and adult 491 
males.   492 
MEP is a primary metabolite of DEP, an LMW phthalate used in varieties of 493 
consumer products including fragrances and personal care products. Sex differences in 494 
MEP concentrations have been explained based on the use of these products, with evidence 495 
of higher MEP levels in females than in males (Saravanabhavan et al. 2014). However, our 496 
finding suggests that higher exposure to DEP may not explain the observed association 497 
among males. The sex-specific relationship may be attributed to either the endocrine 498 
disruptive ability of DEP in relation to sex differences in asthma prevalence (Buckley et al. 499 
2018), or the hormonal influence of the chemical on the functioning of lungs and the immune 500 
systems. It is also plausible that the interactions between gene and environmental exposure 501 
to DEP may have resulted in sex-specific differences and the observed male susceptibility to 502 
asthma prevalence.  503 
Although the pathways through which phthalates induce asthma in humans remain 504 
unclear (Wyatt et al. 2014), animal studies have provided stronger evidence of their 505 
deleterious effects. For example, the metabolites of HMW phthalates, especially MBzP and 506 
MEHP, were shown to bind with and activate the nuclear peroxisome proliferator-activated 507 
receptors (PPAR –alpha and PPAR-gamma), which play a significant role in certain 508 
physiological processes including airway remodeling and inflammation in rodents (Hurst and 509 
Waxman 2003). More recently, in vivo studies have demonstrated that DEHP induces Th2 510 
and Th17 immune responses and airway inflammation in mice (Alfardan et al. 2018), and 511 
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thymic stromal lymphopoietin (TSLP), Th2 immune response and interleukin-7 receptor in 512 
rats (Wand et al. 2018); all of which exacerbates asthma.  513 
Some limitations of the study include the cross-sectional design of NHANES making 514 
it difficult to establish causality in the associations between phthalate exposures and asthma 515 
in children and adults. Phthalate measurements are prone to exposure misclassification via 516 
the use of a single spot urine sample per subject, which may not take into account the 517 
variation of within-person over time. Nevertheless, although phthalate metabolites have 518 
biological half-lives of less than a day (Jepsen et al. 2004; Ferguson et al. 2011), research 519 
has shown that, despite this temporal variability, the measurement of phthalate 520 
concentrations via a single spot urine sample may be a representative of long-term 521 
exposures (Teitelbaum et al. 2008). We were unable to repeat the analysis for children using 522 
spirometry data. This is because FEV1/FVC was considered a poor diagnostic test for 523 
childhood asthma due to a lack of accuracy and precision (Murray et al. 2016) and the 524 
limited number of children classified as asthmatics (< 2%) compared to non-asthmatics 525 
(>98%) (Table 2). This prevented us from investigating if the observed association between 526 
MBzP metabolites and self-reported asthma in children were overestimated or due to 527 
chance. Finally, some children and adults with asthma, particularly of lower socio-economic 528 
status (SES), may not have received a diagnosis of asthma due to lack of healthcare; and 529 
thus, are unaware of their current asthma status.  530 
However, the strengths of the study include using three NHANES waves based on a 531 
representative sample of the US population that is diverse in terms of geographical 532 
distribution, ethnic groups, age, and income. Current asthma was defined using both 533 
subjective (self-reported) and objective (spirometry) measures in adults. Both our primary 534 
and sensitivity analyses were robust in statistical modeling approaches and may be 535 
generalized to the US population. 536 
Conclusions 537 
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Urinary concentrations of phthalate metabolites were not significantly associated with 538 
current asthma in children and adults, apart from a single metabolite. Stratification by sex 539 
revealed that boys and adult males were at increased odds of asthma following exposure to 540 
only MEP; adult females were at decreased odds of asthma following exposure to MCNP 541 
and MCPP. Based on our findings, the potential adverse effect of phthalate exposure on 542 
asthma pathogenesis and/or exacerbations remains controversial, highlighting the need for a 543 
more comprehensive study on phthalate exposure and the occurrence of asthma; ideally, 544 
integrating a well-designed longitudinal follow-up analysis would be more informative. 545 
 546 
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Table 1. Commonly used phthalates, their molecular weights and primary metabolites. Adapted from (Braun et al. 2013; 
Benjamin et al. 2017) 
Commonly used 
phthalates (parent 
compound) 
Abbrev
iation 
Metabolites measured in 
epidemiological studies 
Molecula
r weight                 
(MW) 
Uses/Applications 
High Molecular 
Weight (HMW) 
Phthalates 
    
Di- (2-ethylhexyl) 
phthalate 
DEPH a) Mono-(2-ethylhexyl) 
phthalate (MEHP) 
b) Mono-(2-ethyl-5-oxohexyl) 
phthalate (MEOHP) 
c) Mono-(2-ethyl-5-
hydroxylhexyl) phthalate 
(MEHHP) 
c) Mono-(2-ethyl-5-
carboxylpentyl) phthalate 
(MECPP) 
390.56 Plasticizer for PVC including medical tubing (blood 
bags, syringes and dialysis equipment), construction 
and automotive, some food packaging, flooring and 
floor tiles, toys, solvents in lip sticks, plastic films, 
gloves, shower curtains, wall covering, ethyl cellulose 
resin (such as electric wire, imitation leather, mould 
plastic products, and rain wears. 
Di-isononyl phthalate DiNP a) Mono-(carboxyloctyl) 
phthalate (MCOP) 
418.61  PVC sheeting, building and construction materials, 
foot wears, sealing, several categories of toys (plastic 
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b) Mono-isononyl phthalate 
(MiNP) 
 
books, ball, doll and cartoon characters), paints, 
automotive parts adhesives, printing ink for t-shirts, 
soap packaging, resins, and electrical wires and 
cables, etc. 
Di-isodecyl phthalate DiDP Mono-(carboxylnonyl) 
phthalate (MCNP) 
446.66 Plasticizer in PVC, pharmaceutical pills, food 
wrappers, plastic paste for coating, textile inks, PVC 
    Flooring materials, hollow plastic products such as 
toys, exercise balls, and hoppers, and adhesives. 
Di-n-octyl phthalate DnOP Mono (3-carboxylpropyl) 
phthalate (MCPP) 
390.56 Plasticizer in PVC, paints, lacquers, adhesives, 
flooring tiles. 
Benzylbutyl phthalate BBzP a) Mono-benzyl phthalate 
(MBzP) 
b) Mono (3-carboxylpropyl) 
phthalate (MCPP) 
278.34 Cellulose, varnishes, toys, childcare articles, school 
supplies, children clothes, acetate plastics, personal 
care products (including nail polish and cosmetics) 
and fragrance ingredients. 
Low Molecular 
Weight (LMW) 
Phthalates 
    
Di-butyl phthalate  DBP a) Mono-n-butyl phthalate 
(MnBP) 
b) Mono (3-carboxylpropyl) 
phthalate (MCPP) 
278.34 Cellulose acetate plastics, personal care products, 
varnishes, pharmaceutical coatings, and fragrance 
ingredients. 
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D-imethyl phthalate  DMP Mono-methyl phthalate 
(MMP) 
194.18 Fragrance ingredients for cosmetics, domestic and 
personal care product, adhesives, children’s toys, 
lacquers, paints, plastics and rubbers. 
Di-ethyl phthalate DEP Mono-ethyl phthalate (MEP) 222.24 Personal care items (fragrances), pharmaceutical 
coatings and packaging, dyes, nail polish, perfumes 
as a solvent, ingredient in aspirin coating, surface 
lubricants in food, automotive parts, adhesives and 
plasticizers. 
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Table 2. Demographic and asthma status for all children and subsets sampled for phthalate concentrations, NHANES 2007-2012. 
                                                                                                  Children aged 6- <18 years 
Characteristics 
 
All participants 
(n=11823) 
Participants sampled for 
phthalate concentrations 
(n=2180) 
Age at screening (years), weighted mean (SD, 95% CI) 8.6 (5.2, 8.44-8.74) 11.5 (3.4, 11.27-11.71) 
Sex   
Male, weighted % (n, 95% CI) 50.8 (6037, 49.26-52.25) 50.1 (1095, 47.09-53.00) 
Female, weighted % (n, 95% CI) 49.2 (5786, 47.75-50.74) 49.9 (1085, 46.99-52.91) 
Race/ethnicity, weighted %, (n, 95% CI)   
Non-Hispanic whites  55.5 (3646, 50.57-60.39) 56.1 (619, 50.38-61.62) 
Non-Hispanic Blacks 14.3 (2801,11.99-17.04) 14.7 (551, 12.13-17.73) 
Mexican American Hispanic 15.0 (2983,12.04-18.63) 14.8 (537, 11.48-18.77) 
Others 15.1 (2575, 12.90-17.58) 14.4 (473, 11.74-17.66) 
Waist circumference (cm), weighted mean (SD, 95% CI) 67.8 (16.2, 67.25-68.34) 73.1 (15.4, 72.10-73.99) 
Family income-to-poverty ratio (PIR), weighted % (n, 95% CI)                        
Below poverty (PIR<1), weighted % (n, 95% CI) 24.4 (3823, 21.97-27.03) 23.7 (668, 20.85-26.82) 
At or above poverty (PIR≥1),  75.6 (7052, 72.97-78.03) 76.3 (1333, 73.18-79.15) 
Urinary creatinine (mg/dL), weighted mean (SD, 95% CI) 119.2 (74.2, 114.76-
123.69) 
118.6 (75.3, 113.76-123.36) 
Cotinine levels (ng/mL), weighted % (n, 95% CI)   
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SD: standard deviation; CI: confidence interval; LOD: limit of detection; FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity 
 
 
 
<LOD  (<0.015) 25.9 (1554, 23.03-29.13) 26.8 (457, 22.94-30.99) 
Low (≥0.015 to <10) 70.4 (4855, 67.15-73.42) 68.7 (1322, 64.72-72.47) 
High (≥10) 3.7 (184, 2.96-4.50) 4.5 (63, 3.18-6.33) 
Current asthma based on self-reported questionnaire, 
weighted % (n, 95% CI) 
  
Yes 7.6 (800, 7.13-8.14) 8.1 (177, 6.80-9.71) 
No 92.4 (9700, 91.86-92.87) 91.9 (2003, 90.29-93.20) 
Current asthma based on spirometry FEV1/FVC cut-off, 
weighted % (n, 95% CI) 
  
Yes 1.7 (110, 1.28-2.12) 1.5 (34, 1.02-2.07) 
No 98.3 (5737, 97.88-98.72) 98.6 (1877, 97.93-98.98) 
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Table 3. Demographic and asthma status for all adults and subsets sampled for phthalate concentrations, NHANES 2007-2012 
                                                                                                         Adults aged 18- <80 years 
Characteristics All participants (n=18619) Participants sampled for 
phthalate concentrations 
(n=5585) 
Age at screening (years), weighted mean (SD, 95% CI) 46.1 (17.3, 45.33-46.82) 44.2 (16.1, 43.36-45.00) 
Sex 
Male, weighted % (n, 95% CI) 48.3 (9140, 47.59-49.06) 49.4 (2804, 47.95-50.94) 
Female, weighted % (n, 95% CI) 51.7 (9479, 50.94-52.41) 50.6 (2781, 43.37-52.05) 
Race/ethnicity, weighted % (n, 95% CI) 
Non-Hispanic whites  67.6 (8044, 63.20-71.62) 67.1 (2323, 62.74-71.25) 
Non-Hispanic Blacks 11.6 (4050, 9.60-13.84) 11.9 (1271, 9.80-14.33) 
Mexican American Hispanic 8.4 (2913, 6.48-10.75) 8.3 (893, 6.36-10.78) 
Others 12.5 (3612, 10.70-14.61) 12.7 (1098, 10.81-14.81) 
Waist circumference (cm), weighted mean (SD, 95% CI) 97.9 (16.2, 97.27-98.43) 97.8 (16.7, 97.05-98.60) 
Family income-to-poverty ratio (PIR), weighted % (n, 95% CI)                      
Below poverty (PIR<1),  16.1 (4003, 14.56-17.78) 16.2 (1233, 14.20-18.50) 
At or above poverty (PIR≥1),  83.9 (12834, 82.15-85.44) 83.8 (3837, 81.50-85.80) 
Urinary creatinine (mg/dL), weighted mean (SD, 95% CI) 120.8 (77.9, 117.84-123.81) 121.4 (78.7, 118.28-124.49) 
Cotinine levels (ng/mL), weighted % (n, 95% CI) 
<LOD (<0.015) 24.9 (3724, 23.28-26.69) 25.1 (1130, 22.90-27.35) 
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Low (≥0.015 to <10) 50.0 (8844, 48.47-51.50) 49.2 (2705, 46.83-51.49) 
High (≥10) 25.1 (4216, 23.58-26.60) 25.8 (1379, 23.60-28.10) 
Current asthma based on self-reported questionnaire, weighted % (n, 95% CI) 
Yes 5.9 (1123, 5.29-6.75) 5.7 (349, 4.93-6.47) 
No 94.0 (17463, 93.24-94.71) 94.3 (5227, 93.53-95.07) 
Current asthma based on spirometry FEV1/FVC cut-off, weighted % (n, 95% CI) 
Yes 13.4 (1818, 12.42-14.52) 13.6 (610, 12.19-15.05) 
No 86.6 (12353, 85.48-87.58) 86.4 (4966, 84.95-87.81) 
 
SD: standard deviation; CI: confidence interval; LOD: limit of detection; n: number of observation; FEV1: forced expiratory volume in one 
second; FVC: forced vital capacity 
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Table 4. Distribution of urinary phthalate concentrations for children (aged 6-<18 years), NHANES 2007-2012 
                                                                                                                                                          Percentile 
Metabolite 
(ng/mL) 
Sampl
e size, 
N 
LODmax 
(ng/mL) 
≥ LODmax 
(%)a 
Weighted 
geometric mean 
(95% CI) 
Min 5th 25th 50th 75th 95th max 
LMW 
phthalate 
           
MEP 2106 0.6 99.9 45.2 (39.85-50.45) <LODmax 6.9 22.8 49.5 129.1 588.9 7633.2 
MiBP 2106 0.3 99.6 9.7 (9.05-10.37) <LODmax 1.5 5.4 11.5 22.2 56.2 1163.3 
MnBP 2106 0.6 98.4 18.2 (16.56-19.89) <LODmax 2.3 10.4 22.2 44.4 118.3 101013 
HMW 
phthalate 
           
MBzP 2106 0.3 99.4 10.6 (9.55-11.67) <LODmax 1.2 5.0 12.3 27.3 86.1 617.18 
MCNP 2106 0.5 96.3 3.0 (2.72-3.19) <LODmax 0.5 1.7 3.1 5.5 14.6 334 
MCPP 2106 0.2 98.5 4.0 (3.56-4.39) <LODmax 0.6 1.9 3.8 8.0 24.9 1425.8 
ΣDEHPb 2106 - - 0.2 (0.17-0.21) 0.004 0.03 0.10 0.20 0.40 1.43 15.57 
MEHP 2106 1.1 66.7 2.1 (1.96-2.23) <LODmax <LODmax <LODmax 1.9 4.2 15.3 204.7 
MEHHP 2106 0.7 99.4 16.1 (14.58-17.65) <LODmax 2.2 7.8 17.2 36.5 133.3 1672 
MECPP 2106 0.5 100 27.1 (24.67-29.56) <LODmax 5.0 14.6 28.4 56.4 194.1 1871 
MEOHP 2106 0.6 99.1 10.2 (9.30-11.17) <LODmax 1.5 5.1 11.2 22.8 76.8 1175.1 
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Table 5. Distribution of urinary phthalate concentrations for adults (aged 18-<80 years), NHANES 2007-2012 
                                                                                                                                                          Percentile 
Metabolite 
(ng/mL) 
Sample 
size, N 
LODmax 
(ng/mL) 
≥ LODmax 
(%)a 
Weighted 
geometric mean 
(95% CI) 
Min 5th 25th 50th 75th 95th max 
LMW 
phthalate 
           
MEP 5417 0.6 99.9 63.6 (58.95-68.35) <LODmax 6.8 26.1 72.1 224.3 1285 31660 
MiBP 5417 0.3 98.7 6.5 (6.12-6.90) <LODmax 0.9 3.8 8.1 15.5 40.0 627 
MnBP 5417 0.6 97.2 11.9 (10.96-12.79) <LODmax 1.3 6.8 15.0 30.8 84.8 25863 
HMW 
phthalate 
           
MBzP 5417 0.3 97.8 5.3 (4.93-5.63) <LODmax 0.6 2.5 5.9 13.4 42.3 450.2 
MCNP 5417 0.5 92.7 2.6 (2.42-2.72) <LODmax <LOD 1.2 2.4 4.8 16.2 730.25 
MCPP 5417 0.2 97.4 2.8 (2.54-2.99) <LODmax 0.3 1.2 2.6 5.6 22.4 2597.3 
ΣDEHPb 5417 - - 0.1 (0.13-0.15) 0.003 0.02 0.07 0.14 0.30 1.1 106.72 
MEHP 5417 1.1 62.8 2.1 (1.92-2.20) <LODmax <LODmax <LODmax 1.7 4.0 16.9 1252.7 
MEHHP 5417 0.7 98.5 12.5 (11.52-13.52) <LODmax 1.6 5.9 12.8 27.3 116.3 9326.1 
MECPP 5417 0.5 99.8 19.5 (17.99-20.92) <LODmax 3.1 9.5 19.8 40.7 148.1 15828 
MEOHP 5417 0.6 97.8 7.5 (6.90-8.07) <LODmax 1.0 3.6 7.7 16.1 62.1 6079.9 
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ng/mL: nanogram per millilitre; N : number of participants/urinary samples; LOD: limit of detection;  Min: minimum; 5th: 5th percentile; 25th: 25th 1 
percentile; 50th: 50th percentile; 75th: 75th percentile; 95th: 95th percentile; max: maximum; LMW: low molecular weight; MMP :mono-n-methyl 2 
phthalate; MEP: mono-ethyl phthalate; MiBP: mono-isobutyl phthalate; MnBP: mono-n-butyl phthalate; HWM: high molecular weight; MiNP: 3 
mono-isononyl phthalate; MBzP: mono-benzyl phthalate; MCNP: mono (carboxylnonyl) phthalate; MCPP : mono (3-carboxylpropyl) phthalate; 4 
DEHP: di(2-ethylhexyl) phthalate; MEHP: mono (2-ethylhexyl) phthalate; MEHHP: mono (2-ethyl-5-hydroxylhexyl) phthalate; MECPP: mono (2-5 
ethyl-5-carboxylpentyl) phthalate; MEOHP: mono (2-ethyl-5-oxohexyl) phthalate. 6 
aPercentage of phthalate metabolite concentrations at or above the maximum limit of detection (<LODmax). All concentrations below the LODmax 7 
(<LODmax) were substituted with a value of LODmax divided by square root of two (√2). 8 
bΣDEHP: Molar sum of DEHP metabolites (MEHP, MEHHP, MECPP, and MEOHP) expressed in µmol/L. 9 
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